Bank of America Raises Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $186.00

Sarepta Therapeutics' price objective raised by Bank of America.

The Fly

Recent research reports have been published by other analysts about the stock. Oppenheimer reduced their target price for shares of Sarepta Therapeutics, from $180.00 down to $150.00. They also set an outperform ratings on the stock. This was in a report published on Thursday 9th March. Robert W. Baird raised their price target for Sarepta Therapeutics to $202.00 in a research report on March 1st. Barclays raised their price target on Sarepta Therapeutics in a Friday research report from $170.00 up to $193.00. Citigroup began covering shares of Sarepta Therapeutics on Tuesday, 4th April in a research note. The stock was given a buy recommendation and a price target of $179.00. In a research report published on Friday, 14th April, Mizuho reiterated its buy rating on Sarepta Therapeutics and set a price target of $160.00. Two analysts gave the stock a hold recommendation, and fourteen others have given the stock a buy recommendation. The stock opened Friday at $114.09. The company's 50-day moving average of $129.38, and its 200 day moving average of $129.55. The company's quick ratio is 4.26, its current ratio is 4.63, and it has a debt to equity ratio of 1.73. The company has a $10.63 billion market cap, a PE of -8.99, and a beta value of 1.01. Sarepta Therapeutics' 52-week low is $70.32 while its 52-week high is $159.89.

The last time ) announced its quarterly results was on May 2nd. The biotechnology firm reported ($0.97) in earnings per share for the quarter. This was $0.49 higher than analysts' expectations of ($1.46). Revenue for the quarter was $253.50 millions, which is higher than the $241.47-million consensus estimate. Sarepta Therapeutics's negative net margin was 114.30%, and its negative return on equity was 128.64%. Revenue was up by 20.2% from the same quarter of last year. In the same quarter of last year, Sarepta Therapeutics earned ($1.20). Analysts expect Sarepta Therapeutics to post -10.9 earnings a share in the current year.

Sarepta Therapeutics Institutional Trading

Recently, hedge funds and institutional investors bought and sold shares in the company. KB Financial Partners LLC purchased a new position of shares in Sarepta Therapeutics worth approximately $36,000 during the first quarter. FourThought Financial LLC increased its stake in Sarepta Therapeutics during the third quarter by 43.5%. FourThought Financial LLC owns now 297 shares worth $33,000 of the stock of the biotechnology firm after buying an additional 90 during the last quarterly. Armstrong Advisory Group Inc. purchased a new Sarepta Therapeutics position during the fourth quarter, valued at about $39,000. Harvest Fund Management Co. Ltd bought a new Sarepta Therapeutics position in the first-quarter valued at around $49,000. Clearstead Advisors LLC also acquired a stake in Sarepta Therapeutics worth $49,000 during the first quarter. Currently, 85.59% is owned by hedge funds and institutional investors.

Sarepta Therapeutics

Get Rating

Sarepta Therapeutics, Inc., a biopharmaceutical commercial-stage company, focuses its efforts on the development and discovery of RNA-targeted therapies, gene therapy, and other genetic treatment modalities to treat rare diseases. Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment rare diseases.

Continue Reading offers a FREE daily email newsletter